Related Experiment Video
Updated: Mar 12, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Progress in the treatment of mature T-cell lymphoma
1Department of Oncology and Hematology, Shimane University Cancer Center.
Abstract:
Treatment outcomes of malignant lymphoma have improved due to the discovery of novel chemotherapeutic and molecular targeted agents as well as advances in their combination uses. However, the prognosis of T-cell lymphoma remains poorer than that of B-cell lymphomas, and progress is slow. The reasons include their chemotherapeutic resistant nature and the absence of effective antibody agents for T-cell lymphomas. The number of T-cell lymphoma subtypes increased from 21 in the WHO classification 2008 to 29 in the WHO classification 2016. This means that T-cell lymphomas are heterogeneous. T-cell lymphomas can be divided to ALK-positive anaplastic lymphoma (ALCL) with a good prognosis and others with poorer prognoses. ALK-positive ALCL can be successfully treated with CHOP, but the others cannot. P-glycoprotein resistant anthracyclines, etoposide, or hematopoietic stem cell transplantations are increasingly applied to improve outcomes, but no standard treatment approach has yet been established. Regarding relapsed/refractory T-cell lymphoma, many novel agents are currently under development. The treatment outcomes of T-cell lymphoma need to be improved by applying innovative strategies including further novel agents.
Insights
Treatment outcomes for T-cell lymphoma lag behind B-cell lymphomas due to chemoresistance and lack of targeted therapies. Innovative strategies and novel agents are crucial for improving prognosis in these heterogeneous cancers.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Malignant lymphoma treatment has advanced with novel agents, yet T-cell lymphomas (TCL) show poorer outcomes compared to B-cell lymphomas.
- TCL are characterized by chemotherapeutic resistance and a lack of effective antibody-based therapies.
- The heterogeneity of TCL is increasing, with subtypes rising from 21 (WHO 2008) to 29 (WHO 2016).
Purpose of the Study:
- To highlight the challenges in T-cell lymphoma treatment.
- To emphasize the need for improved therapeutic strategies for TCL.
- To discuss the potential of novel agents in managing relapsed/refractory TCL.
Main Methods:
- Review of current literature on T-cell lymphoma treatment outcomes.
- Analysis of the heterogeneity and classification of T-cell lymphomas.
- Discussion of established and emerging therapeutic approaches, including chemotherapy, targeted agents, and stem cell transplantation.
Main Results:
- T-cell lymphomas exhibit poorer prognoses than B-cell lymphomas, attributed to chemoresistance and limited targeted treatments.
- ALK-positive anaplastic lymphoma (ALCL) shows a good prognosis with CHOP, unlike other TCL subtypes.
- Established treatments like anthracyclines and etoposide, along with stem cell transplantation, are used, but standard approaches for relapsed/refractory TCL are lacking.
Conclusions:
- Significant unmet needs exist in T-cell lymphoma treatment, necessitating innovative therapeutic strategies.
- Further development and application of novel agents are essential for improving outcomes in relapsed/refractory TCL.
- Addressing the heterogeneity of TCL is critical for developing effective, subtype-specific treatments.
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...